Medical treatment for pulmonary fibrosis: Current trends, concepts, and prospects

Clinics in Chest Medicine

Volumn 25, Issue 4 SPEC.ISS., 2004, Pages 759-772

  Brown, Kevin K ^a,b   Raghu, Ganesh ^c  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; BETA INTERFERON; COLCHICINE; ENDOTHELIN; GAMMA INTERFERON; ICOSANOID; IMATINIB; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID; OMEGA INTERFERON; PENICILLAMINE; PIRFENIDONE; PREDNISONE; RAPAMYCIN; RELAXIN; SURAMIN; THALIDOMIDE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; NONHUMAN; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

EID: 9344234386     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2004.08.003     Document Type: Review

References (130)

1. American Thoracic Society (ATS) and the European Respiratory Society (ERS) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement Am J Respir Crit Care Med 161 2000 646 664
2. J.A. Bjoraker, J.H. Ryu, M.K. Edwin, J.L. Myers, H.D. Tazelaar, and D.R. Schroeder Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 157 1998 199 203
3. J.S. Vourlekis, M.I. Schwarz, and R.M. Cherniack The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis Am J Med 116 2004 662 668
4. W.D. Travis, K. Matsui, and J. Moss Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia Am J Surg Pathol 24 2000 19 33
5. R.J. Mason, M.I. Schwarz, and G.W. Hunninghake NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future Am J Respir Crit Care Med 160 1999 1771 1777
6. J.J. Silverman, and T.J. Talbot Diffuse interstital fibrosis camouflaged by hypermetabolism and cardiac failure: antemorten diagnosis with biopsy and catheterization studies Ann Intern Med 38 1953 1326 1338
7. C.B. Carrington, E.A. Gaensler, and R.E. Coutu Natural history and treated course of usual and desquamative interstitial pneumonia N Engl J Med 298 1978 801 809
8. A. Xaubet, C. Agusti, and P. Luburich Is it necessary to treat all patients with idiopathic pulmonary fibrosis? Sarcoidosis Vasc Diffuse Lung Dis 18 2001 289 295
9. M. Turner-Warwick, B. Burrows, and A. Johnson Cryptogenic fibrosing alveolitis: clinical features and their influence on survival Thorax 35 1980 171 180
10. T.E. King Jr, J.A. Tooze, and M.I. Schwarz Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model Am J Respir Crit Care Med 164 2001 1171 1181
11. A.G. Nicholson, T.V. Colby, and R.M. du Bois The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis Am J Respir Crit Care Med 162 2000 2213 2217
12. W.W. Douglas, J.H. Ryu, and D.R. Schroeder Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival Am J Respir Crit Care Med 161 2000 1172 1178
13. D.A. Schwartz, R.A. Helmers, and J.R. Galvin Determinants of survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 149 1994 450 454
14. K.R. Flaherty, G.B. Toews, and W.D. Travis Clinical significance of histological classification of idiopathic interstitial pneumonia Eur Respir J 19 2002 275 283
15. D.A. Zisman, J.P. Lynch 3rd, and G.B. Toews Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids Chest 117 2000 1619 1626
16. C.S. Dayton, D.A. Schwartz, and R.A. Helmers Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies Chest 103 1993 69 73
17. M. Turner-Warwick, B. Burrows, and A. Johnson Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival Thorax 35 1980 593 599
18. H.R. Collard, T.E. King Jr, B.B. Bartelson, J.S. Vourlekis, M.I. Schwarz, and K.K. Brown Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 168 5 2003 538 542
19. R. Erbes, T. Schaberg, and R. Loddenkemper Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 111 1997 51 57
20. P.I. Latsi, R.M. du Bois, A.G. Nicholson, T.V. Colby, D. Bisirtzoglou, and A. Nikolakopoulou Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends Am J Respir Crit Care Med 168 5 2003 531 537
21. K.R. Flaherty, J.A. Mumford, S. Murray, E.A. Kazerooni, B.H. Gross, and T.V. Colby Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia Am J Respir Crit Care Med 168 5 2003 543 548
22. V.N. Lama, K.R. Flaherty, and G.B. Toews Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia Am J Respir Crit Care Med 168 2003 1084 1090
23. D.A. Schwartz, D.S. Van Fossen, and C.S. Davis Determinants of progression in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 149 1994 444 449
24. A.U. Wells, D.M. Hansell, and M.B. Rubens The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis Am Rev Respir Dis 148 1993 1076 1082
25. A.U. Wells, M.B. Rubens, and R.M. du Bois Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern AJR Am J Roentgenol 161 1993 1159 1165
26. S.E. Gay, E.A. Kazerooni, and G.B. Toews Idiopathic pulmonary fibrosis: predicting response to therapy and survival Am J Respir Crit Care Med 157 1998 1063 1072
27. Lynch DG, Webb JD, Bradford WA, Starko K., IPF Study group. HRCT findings at baseline and followup in patients with idiopathic pulmonary fibrosis (IPF) in a Phase 3, randomized, double-blind, placebo-controlled trial of interferon gamma-1b. Presented at the International Conference of the American Thoracic Society, Orlando, FL, May 21-26, 2004.
28. N. Mogulkoc, M.H. Brutsche, and P.W. Bishop Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation Am J Respir Crit Care Med 164 2001 103 108
29. M.A. Johnson, S. Kwan, and N.J. Snell Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis Thorax 44 1989 280 288
30. T.E. King Jr, M.I. Schwarz, and K. Brown Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality Am J Respir Crit Care Med 164 2001 1025 1032
31. H.R. Collard, J.H. Ryu, and W.W. Douglas Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis Chest 125 2004 2169 2174
32. K.R. Flaherty, G.B. Toews, and J.P. Lynch 3rd Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival Am J Med 110 2001 278 282
33. G. Raghu, W.J. Depaso, and K. Cain Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial Am Rev Respir Dis 144 1991 291 296
34. W.W. Douglas, J.H. Ryu, S.J. Swensen Members of the Lung Study Group Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study Am J Respir Crit Care Med 158 1998 220 225
35. M. Selman, G. Carrillo, and J. Salas Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial Chest 114 1998 507 512
36. S.H. Phan, and S.L. Kunkel Lung cytokine production in bleomycin-induced pulmonary fibrosis Exp Lung Res 18 1992 29 43
37. A.O. Williams, K.C. Flanders, and U. Saffiotti Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer Am J Pathol 142 1993 1831 1840
38. C.E. Rube, D. Uthe, and K.W. Schmid Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation Int J Radiat Oncol Biol Phys 47 2000 1033 1042
39. S.N. Giri, D.M. Hyde, and M.A. Hollinger Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice [comments] Thorax 48 1993 959 966
40. Q. Wang, Y. Wang, and D.M. Hyde Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters Thorax 54 1999 805 812
41. R.G. Crystal, P.B. Bitterman, and B. Mossman Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group Am J Respir Crit Care Med 166 2002 236 246
42. N. Khalil, R.N. O'Connor, and K.C. Flanders TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study Am J Respir Cell Mol Biol 14 1996 131 138
43. T.J. Broekelmann, A.H. Limper, and T.V. Colby Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis Proc Natl Acad Sci USA 88 1991 6642 6646
44. M.F. Cordeiro Technology evaluation: lerdelimumab, Cambridge Antibody Technology Curr Opin Mol Ther 5 2003 199 203
45. A. Leask, A. Holmes, and D.J. Abraham Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis Curr Rheumatol Rep 4 2002 136 142
46. J.T. Allen, R.A. Knight, and C.A. Bloor Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis Am J Respir Cell Mol Biol 21 1999 693 700
47. J. Gauldie, T. Galt, and M.A. Anzano SMAD3 KO mouse is resistant to gene based TGF-beta1 induced fibrosis. Lack of Activation of CTGF Am J Respir Crit Care Med 164 2001 A759
48. L.M. Pfeffer, J.S. Murphy, and I. Tamm Interferon effects on the growth and division of human fibroblasts Exp Cell Res 121 1979 111 120
49. A.M. Cornelissen, J.W. Von den Hoff, and J.C. Maltha Effects of interferons on proliferation and collagen synthesis of rat palatal wound fibroblasts Arch Oral Biol 44 1999 541 547
50. M.J. Dans, and R. Isseroff Inhibition of collagen lattice contraction by pentoxifylline and interferon-alpha, -beta, and -gamma J Invest Dermatol 102 1994 118 121
51. A. Billiau, H. Heremans, and K. Vermeire Immunomodulatory properties of interferon-gamma. An update Ann N Y Acad Sci 856 1998 22 32
52. N. Berkman, S. Kremer, and R. Or Human recombinant interferon-alpha2a and interferon-alphaA/D have different effects on bleomycin-induced lung injury Respiration (Herrlisheim) 68 2001 169 177
53. R.M. Rose, C.R. O'Donnell, and C. Croteau Phase II/III study of recombinant interferon-beta (IFN-B) therapy in patients with advanced idiopathic pulmonary fibrosis (IPF) Am Rev Respir Dis 141 1990 A58
54. Raghu G, Bozic CR, Brown K, et al. Feasibility of a trial of interferon beta-1A (IFN-beta-1A) in the treatment of idiopathic pulmonary fibrosis (IPF). Presented at the International Conference of the American Thoracic Society, San Francisco, CA, May 18-23, 2001.
55. A.S. Narayanan, J. Whithey, and A. Souza Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts Chest 101 1992 1326 1331
56. A. Diaz, and S.A. Jimenez Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms Int J Biochem Cell Biol 29 1997 251 260
57. H.A. Jaffe, Z. Gao, and Y. Mori Selective inhibition of collagen gene expression in fibroblasts by an interferon-gamma transgene Exp Lung Res 25 1999 199 215
58. O. Eickelberg, A. Pansky, and E. Koehler Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts FASEB J 15 2001 797 806
59. S.D. Oldroyd, G.L. Thomas, and G. Gabbiani Interferon-gamma inhibits experimental renal fibrosis Kidney Int 56 1999 2116 2127
60. K. Tamai, H. Ishikawa, and A. Mauviel Interferon-gamma coordinately upregulates matrix metalloprotease (MMP)- 1 and MMP-3, but not tissue inhibitor of metalloproteases (TIMP), expression in cultured keratinocytes J Invest Dermatol 104 1995 384 390
61. R. Ziesche, E. Hofbauer, and K. Wittmann A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis N Engl J Med 341 1999 1264 1269
62. S. Kalra, J.P. Utz, and J.H. Ryu Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis Mayo Clin Proc 78 2003 1082 1087
63. G. Raghu, C. Spada, and Y. Otaki Interferon-gamma in the treatment of advanced idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia (NSIP-F): prospective, preliminary clinical observations in one center Chest 120 2001 185[S]
64. S.N. Iyer, D.M. Hyde, and S.N. Giri Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation Inflammation 24 2000 477 491
65. S.N. Iyer, G. Gurujeyalakshmi, and S.N. Giri Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J Pharmacol Exp Ther 291 1999 367 373
66. G. Raghu, W.C. Johnson, and D. Lockhart Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study Am J Respir Crit Care Med 159 1999 1061 1069
67. S. Nagai, K. Hamada, M. Shigematsu, M. Taniyama, S. Yamauchi, and T. Izumi Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis Intern Med 41 12 2002 1118 1123
68. W.A. Gahl, M. Brantly, J. Troendle, N.A. Avila, A. Padua, and C. Montalvo Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome Mol Genet Metab 76 3 2002 234 242
69. Raghu G. Pirfenidone: an antifibrotic agent that holds promises for IPF. Presented at the International Conference of the American Thoracic Society, Orlando, FL, USA, May 21-26, 2004.
70. J. Behr, K. Maier, and B. Degenkolb Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am J Respir Crit Care Med 156 1997 1897 1901
71. A.M. Cantin, R.C. Hubbard, and R.G. Crystal Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis Am Rev Respir Dis 139 1989 370 372
72. I. Rahman, and W. MacNee Oxidative stress and regulation of glutathione in lung inflammation Eur Respir J 16 2000 534 554
73. Y. Kapanci, A. Desmouliere, and J.C. Pache Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha Am J Respir Crit Care Med 152 1995 2163 2169
74. R.A. Rippe, L.W. Schrum, and B. Stefanovic NF-kappaB inhibits expression of the alpha1(I) collagen gene DNA Cell Biol 18 1999 751 761
75. P.F. Piguet, M.A. Collart, and G.E. Grau Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis J Exp Med 170 1989 655 663
76. P.F. Piguet, S. Kaufman, and C. Barazzone Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis Int J Exp Pathol 78 1997 43 48
77. P.F. Piguet, and C. Vesin Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice [see comments] Eur Respir J 7 1994 515 518
78. Y. Zhang, T.C. Lee, and B. Guillemin Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure J Immunol 150 1993 4188 4196
79. P.F. Piguet, C. Ribaux, and V. Karpuz Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis Am J Pathol 143 1993 651 655
80. M. Whyte, R. Hubbard, and R. Meliconi Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms Am J Respir Crit Care Med 162 2000 755 758
81. A. Niden, M. Koss, and C.T. Boylen An open label pilot study to determine the potential efficacy of TNFR:FC (Enbrel Etanercept) in the treatment of usual interstitial pneumonitits (UIP) Am J Respir Crit Care Med 163 2001 A42
82. K.A. Fagan, I.F. McMurtry, and D.M. Rodman Role of endothelin-1 in lung disease Respir Res 2 2001 90 101
83. M.A. McMillen, and B.E. Sumpio Endothelins: polyfunctional cytokines J Am Coll Surg 180 1995 621 637
84. G. Sun, M.A. Stacey, and A. Bellini Endothelin-1 induces bronchial myofibroblast differentiation Peptides 18 1997 1449 1451
85. E. Guarda, L.C. Katwa, and P.R. Myers Effects of endothelins on collagen turnover in cardiac fibroblasts Cardiovasc Res 27 1993 2130 2134
86. T.J. Mariani, J.D. Roby, and R.P. Mecham Localization of type I procollagen gene expression in silica-induced granulomatous lung disease and implication of transforming growth factor-beta as a mediator of fibrosis Am J Pathol 148 1996 151 164
87. S.E. Mutsaers, M.L. Foster, and R.C. Chambers Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats Am J Respir Cell Mol Biol 18 1998 611 619
88. B. Hocher, A. Schwarz, and K.A. Fagan Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice Am J Respir Cell Mol Biol 23 2000 19 26
89. S.H. Park, D. Saleh, and A. Giaid Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist Am J Respir Crit Care Med 156 1997 600 608
90. S.E. Mutsaers, R.P. Marshall, and N.R. Goldsack Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats Pulm Pharmacol Ther 11 1998 221 225
91. M. Sofia, M. Mormile, and S. Faraone Increased endothelin-like immunoreactive material on bronchoalveolar lavage fluid from patients with bronchial asthma and patients with interstitial lung disease Respiration (Herrlisheim) 60 1993 89 95
92. M. Uguccioni, L. Pulsatelli, and B. Grigolo Endothelin-1 in idiopathic pulmonary fibrosis J Clin Pathol 48 1995 330 334
93. A. Giaid, R.P. Michel, and D.J. Stewart Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis Lancet 341 1993 1550 1554
94. A.D. Cambrey, N.K. Harrison, and K.E. Dawes Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro Am J Respir Cell Mol Biol 11 1994 439 445
95. C. Odoux, B. Crestani, and G. Lebrun Endothelin-1 secretion by alveolar macrophages in systemic sclerosis Am J Respir Crit Care Med 156 1997 1429 1435
96. T.R. Mosmann, H. Cherwinski, and M.W. Bond Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins J Immunol 136 1986 2348 2357
97. A.E. Postlethwaite, M.A. Holness, and H. Katai Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4 J Clin Invest 90 1992 1479 1485
98. K. Zhang, M. Gharaee-Kermani, and M.L. Jones Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis J Immunol 153 1994 4733 4741
99. M. Gharaee-Kermani, and S.H. Phan Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis Am J Respir Cell Mol Biol 16 1997 438 447
100. M. Gharaee-Kermani, B. McGarry, and N. Lukacs The role of IL-5 in bleomycin-induced pulmonary fibrosis J Leukoc Biol 64 1998 657 666
101. F. Huaux, J. Louahed, and B. Hudspith Role of interleukin-10 in the lung response to silica in mice Am J Respir Cell Mol Biol 18 1998 51 59
102. F. Huaux, M. Arras, and A. Vink Soluble tumor necrosis factor (TNF) receptors p55 and p75 and interleukin-10 downregulate TNF-alpha activity during the lung response to silica particles in NMRI mice Am J Respir Cell Mol Biol 21 1999 137 145
103. H. Furuie, H. Yamasaki, and M. Suga Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis Eur Respir J 10 1997 787 794
104. S.P. Atamas, V.V. Yurovsky, and R. Wise Production of type 2 cytokines by CD8 + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis Arthritis Rheum 42 1999 1168 1178
105. T.J. Standiford, S.L. Kunkel, and S.H. Phan Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells J Biol Chem 266 1991 9912 9918
106. H.N. Antoniades, T. Galanopoulos, and J. Neville-Golden Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products Proc Natl Acad Sci USA 89 1992 3942 3946
107. W.A. Wallace, E.A. Ramage, and D. Lamb A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA) Clin Exp Immunol 101 1995 436 441
108. S. Majumdar, D. Li, and T. Ansari Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies Eur Respir J 14 1999 251 257
109. D.C. Zeldin The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis Am J Respir Crit Care Med 165 2002 146 147
110. S.H. Phan, B.M. McGarry, and K.M. Loeffler Binding of leukotriene C4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro Biochemistry 27 1988 2846 2853
111. L. Baud, J. Perez, and M. Denis Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin J Immunol 138 1987 1190 1195
112. J. Wilborn, M. Bailie, and M. Coffey Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis J Clin Invest 97 1996 1827 1836
113. M. Peters-Golden, M. Bailie, and T. Marshall Protection from pulmonary fibrosis in leukotriene-deficient mice Am J Respir Crit Care Med 165 2002 229 235
114. S.H. Gavett, S.L. Madison, and P.C. Chulada Allergic lung responses are increased in prostaglandin H synthase-deficient mice J Clin Invest 104 1999 721 732
115. C.B. Keerthisingam, R.G. Jenkins, and N.K. Harrison Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice Am J Pathol 158 2001 1411 1422
116. J. Wilborn, L.J. Crofford, and M.D. Burdick Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2 J Clin Invest 95 1995 1861 1868
117. G.H. Gibbons The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling Am J Hypertens 11 1998 177S 181S
118. K.T. Weber Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair Semin Nephrol 17 1997 467 491
119. G. Wolf, U. Haberstroh, and E.G. Neilson Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells Am J Pathol 140 1992 95 107
120. W.F. Ward, A. Molteni, and C.H. Ts'ao Radiation-induced endothelial dysfunction and fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor CL242817 Radiat Res 117 1989 342 350
121. D.J. Loskutoff, and J.P. Quigley PAI-1, fibrosis, and the elusive provisional fibrin matrix J Clin Invest 106 2000 1441 1443
122. D.T. Eitzman, R.D. McCoy, and X. Zheng Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene J Clin Invest 97 1996 232 237
123. I. Kotani, A. Sato, and H. Hayakawa Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis Thromb Res 77 1995 493 504
124. M. Burk, R.L. Robinson, E. Elamin, and H. Jenad Angiotensin blockade improves survival in usual interstitial pneumonitis Chest 122 2002 75S
125. Raghu G, Safrin S, Weycker K, et al. Association of statins and angiotension-converting enzyme inhibitor use with survival and disease progression in patients with idiopathic pulmonary fibrosis (IPF). Presented at the International Conference of the American Thoracic Society, Orlando, FL, May 21-26, 2004.
126. A. Estrada, M. Mejia, J. Morales, T. Suarez, M. Gaxiola, and J. Williams Inhaled Beclomethasone and colchicine verses inhaled beclomethasone, colchicine and captopril in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2000 A528
127. L.W. Wang, X.L. Fu, and R. Clough Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat Res 153 2000 405 410
128. E. Lappi-Blanco, Y. Soini, and P. Paakko Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia Lung 177 1999 367 376
129. A. Tan, H. Levrey, and C. Dahm Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders Am J Respir Crit Care Med 159 1999 220 227
130. M. Burk, R.L. Robinson, E. Elamin, and H. Jenad Statins improve survival in usual interstitial pneumonitis [abstract] Chest 122 2002 150S